Amyloid PET is a cost-effective exam to monitor Donanemab treatment in Alzheimer's disease.
- DOI
- 10.1007/s10072-026-09535-x
- Published
- 2026 Nov 6
- Container
- Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10072-026-09535-x,
title = {Amyloid PET is a cost-effective exam to monitor Donanemab treatment in Alzheimer's disease.},
author = {Tábuas-Pereira M and Moreira AP and Castelo-Branco M and Abrunhosa A and Santana I},
year = {2026},
journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology},
doi = {10.1007/s10072-026-09535-x},
url = {https://doi.org/10.1007/s10072-026-09535-x}
}RIS
TY - JOUR TI - Amyloid PET is a cost-effective exam to monitor Donanemab treatment in Alzheimer's disease. AU - Tábuas-Pereira M AU - Moreira AP AU - Castelo-Branco M AU - Abrunhosa A AU - Santana I PY - 2026 JO - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology DO - 10.1007/s10072-026-09535-x UR - https://doi.org/10.1007/s10072-026-09535-x ER -
APA
M, T., AP, M., M, C., A, A., & I, S. (2026). Amyloid PET is a cost-effective exam to monitor Donanemab treatment in Alzheimer's disease.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. https://doi.org/10.1007/s10072-026-09535-x
Source records
- pubmed · retrieved 2026-11-11T03:30:38.616Z